Search Results - "Cutz, J.C"

The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario by Djalalov, S, Graham, D.M, Beca, J, Hoch, J.S, Tsao, M.S, Cutz, J.C, Leighl, N

Get full text

Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada) by Djalalov, S, Beca, J, Hoch, J.S, Krahn, M.D, Tsao, M.S, Cutz, J.C, Leighl, N

Get full text

Cost-Effectiveness Of Eml4-Alk Fusion Testing In Combination With Crizotinib Treatment For Patients With Advanced Non-Small Cell Lung Cancer Living In Ontario by Djalalov, S, Hoch, J.S, Beca, J, Krahn, M, Tsao, M.S, Cutz, J.C, Leighl, N

Get full text

Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario by Lim, C, Sekhon, H S, Cutz, J C, Hwang, D M, Kamel-Reid, S, Carter, R F, Santos, G da Cunha, Waddell, T, Binnie, M, Patel, M, Paul, N, Chung, T, Brade, A, El-Maraghi, R, Sit, C, Tsao, M S, Leighl, N B

“…Although molecular testing has become standard in managing advanced nonsquamous non-small-cell lung cancer (nsclc), most patients undergo minimally invasive…”
Get full text

Crizotinib inhibition of ROS1- positive tumours in advanced non-small-cell lung cancer: a Canadian perspective by Bebb, D G, Agulnik, J, Albadine, R, Banerji, S, Bigras, G, Butts, C, Couture, C, Cutz, J C, Desmeules, P, Ionescu, D N, Leighl, N B, Melosky, B, Morzycki, W, Rashid-Kolvear, F, Lab, Clin, Sekhon, H S, Smith, A C, Stockley, T L, Torlakovic, E, Xu, Z, Tsao, M S

“…The ros1 kinase is an oncogenic driver in non-small-cell lung cancer (nsclc). Fusion events involving the gene are found in 1%-2% of nsclc patients and lead to…”
Get full text

PCN128 - The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario by Djalalov, S., Graham, D.M., Beca, J., Hoch, J.S., Tsao, M.S., Cutz, J.C., Leighl, N.

Get full text

PCN105 - Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada) by Djalalov, S., Beca, J., Hoch, J.S., Krahn, M.D., Tsao, M.S., Cutz, J.C., Leighl, N.

Get full text

PCN82 - Cost-Effectiveness Of Eml4-Alk Fusion Testing In Combination With Crizotinib Treatment For Patients With Advanced Non-Small Cell Lung Cancer Living In Ontario by Djalalov, S., Hoch, J.S., Beca, J., Krahn, M., Tsao, M.S., Cutz, J.C., Leighl, N.

Get full text

Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care? by VanderMeer, R, Chambers, S, Van Dam, A, Cutz, J C, Goffin, J R, Ellis, P M

“…Histologic and molecular subtyping have become increasingly important as predictors of treatment benefit in lung cancer. The objective of the present study was…”
Get full text